Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

747416

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government when they will publish their response to the Accelerated Access Review of innovative medicines and medical technologies.
tabling member printed	Lord Lansley
uin	HL380
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL381 HL383 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747417

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they intend to establish the Accelerated Access Partnership as recommended in their Accelerated Access Review; and if so when.
tabling member printed	Lord Lansley
uin	HL381
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL380 HL383 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747418

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether a strategic commercial unit will be established within NHS England, as recommended in the Accelerated Access Review, and if so, when.
tabling member printed	Lord Lansley
uin	HL382
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>Consistent with recommendations set out in the Accelerated Access Review, NHS England continues to develop its commercial capacity and capability in relation to medicines procurement as well as the negotiation of bespoke commercial access arrangements for high cost drugs. As part of this, the Commercial Medicines Unit transferred across from the Department to NHS England on 1 April 2017. NHS England is currently in the process of recruiting to a number of other key posts to support the commercial function more broadly.</p> answering member printed Lord O'Shaughnessy question first answered 11/07/2017 14:30:38 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747419

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government what plans they have to introduce a "transformative designation", as proposed in the Accelerated Access Review, for the most strategically important products for the NHS.
tabling member printed	Lord Lansley
uin	HL383
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>In October 2016 the Accelerated Access Review set out a vision of faster patient access to 21st century medicines and medical technologies, making the United Kingdom a world leading place to design, develop and deploy medical innovations.</p><p> </p><p>The review made several recommendations to ensure that patients get new drugs and treatments faster while the National Health Service gets best value for money and remains at the forefront of innovation. The Government and its key delivery partners are reviewing the review’s recommendations and will respond in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL380 HL381 question first answered 11/07/2017 13:59:51 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	123 label Biography information for Lord Lansley

747465

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sustainability and Transformation Partnerships: Bassetlaw and South Yorkshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what costs have been (a) incurred to date and (b) committed for future periods for the development and management of the South Yorkshire and Bassetlaw Sustainability and Transformation Plan.
tabling member constituency	Barnsley East
tabling member printed	Stephanie Peacock
uin	2652
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>Sustainability and Transformation Partnerships (STP) have been developed by local areas. In South Yorkshire and Bassetlaw this includes eight clinical commissioning groups, and multiple National Health Service provider trusts and local authorities. These partners are contributing from their own staff resources to support the multiple programmes and work streams set out in the plan, and staff are working on the STP in addition to their other management roles. As a result, we do not hold the total cost of developing the STP.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/07/2017 15:40:56 answering member 4067 label Biography information for Steve Brine
tabling member	4607 label Biography information for Stephanie Peacock

747515

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Streptococcus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress his Department has made on reviewing UK National Screening Committee guidance on Group B strep prevention; and if he will make a statement.
tabling member constituency	Mid Sussex
tabling member printed	Sir Nicholas Soames
uin	2421
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>The United Kingdom National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy, using research evidence, pilot programmes and economic evaluation; it assesses the evidence for programmes against a set of internationally recognised criteria. Guidance on early onset neonatal Group B Streptococcus (GBS) and other neonatal disease is provided by the Royal College of Obstetricians and Gynaecologists and National Institute for Health and Care Excellence.</p><p> </p><p>Following the UK NSC’s meeting in February 2017, the Minister accepted the UK NSC’s recommendation that a population based screening programme for GBS carriage should not be offered. This is because there is insufficient evidence to demonstrate that the benefits to be gained from screening would outweigh the harms.</p><p> </p><p>Although a population screening programme has not been recommended, the Chief Scientific Advisor recommended that the National Institute of Health Research should commission a clinical trial to compare universal screening for GBS against usual-risk based care. The Minister approved this and it is expected that the trial will provide better quality evidence to assess the clinical effectiveness, benefits and harms of a screening programme.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 2420 question first answered 06/07/2017 14:06:12 answering member 1542 label Biography information for Philip Dunne
tabling member	116 label Biography information for Lord Soames of Fletching

747518

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Streptococcus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the National Institute for Health Research will begin the clinical trial comparing universal screening for Group B strep carriage in late pregnancy with usual risk-based care.
tabling member constituency	Mid Sussex
tabling member printed	Sir Nicholas Soames
uin	2419
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>The National Institute for Health Research will launch the expression of interest for the trial to compare universal screening for Group B strep carriage in late pregnancy with usual risk-based care shortly. Following a full Health Technology Assessment board commissioning process, it is anticipated that the pilot phase of the trial will start at the beginning of 2019.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 06/07/2017 14:08:43 answering member 1542 label Biography information for Philip Dunne
tabling member	116 label Biography information for Lord Soames of Fletching

747519

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Streptococcus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plans to review Group B strep prevention strategies to align the UK with international best practice in preventing early-onset Group B Strep.
tabling member constituency	Mid Sussex
tabling member printed	Sir Nicholas Soames
uin	2420
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>The United Kingdom National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy, using research evidence, pilot programmes and economic evaluation; it assesses the evidence for programmes against a set of internationally recognised criteria. Guidance on early onset neonatal Group B Streptococcus (GBS) and other neonatal disease is provided by the Royal College of Obstetricians and Gynaecologists and National Institute for Health and Care Excellence.</p><p> </p><p>Following the UK NSC’s meeting in February 2017, the Minister accepted the UK NSC’s recommendation that a population based screening programme for GBS carriage should not be offered. This is because there is insufficient evidence to demonstrate that the benefits to be gained from screening would outweigh the harms.</p><p> </p><p>Although a population screening programme has not been recommended, the Chief Scientific Advisor recommended that the National Institute of Health Research should commission a clinical trial to compare universal screening for GBS against usual-risk based care. The Minister approved this and it is expected that the trial will provide better quality evidence to assess the clinical effectiveness, benefits and harms of a screening programme.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 2421 question first answered 06/07/2017 14:06:12 answering member 1542 label Biography information for Philip Dunne
tabling member	116 label Biography information for Lord Soames of Fletching

747541

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Reciprocal Arrangements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much his Department has paid for the medical treatment of UK citizens in other EU member states in each of the last five years.
tabling member constituency	Hendon
tabling member printed	Dr Matthew Offord
uin	2506
answer	answer is ministerial correction date of answer 11/07/2017 answer text <p>The Department on behalf of the United Kingdom Government reimburses other European Economic Area (EEA) countries and Switzerland for the cost of providing treatment to people we are responsible for under European Union law, irrespective of nationality. In the same way, other EEA countries and Switzerland reimburse the UK for the cost of the National Health Service providing treatment to people they are responsible for under EU law, including UK nationals insured in another EEA country or Switzerland.</p><p> </p><p>Member State claims against the UK are in local currency so totals are significantly affected by the exchange rate at the time of payment and can mean a difference of millions of pounds. Member States can submit claims up to 18 months in arrears so claims for any 12 month period do not necessarily reflect treatment provided in that period.</p><p> </p><p>Requested figures are provided in the attached document rounded to the nearest pound.</p><p> </p><p>Figures for 2016–17 should be published over the summer.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 11/07/2017 16:36:40 answering member 1542 label Biography information for Philip Dunne attachment 1 file name PQ2506 attached table.xlsx title PQ2506 attached table
tabling member	4006 label Biography information for Dr Matthew Offord

747554

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Homelessness: Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information his Department holds on medical conditions experienced by homeless people in each of the last five years.
tabling member constituency	Liverpool, Riverside
tabling member printed	Mrs Louise Ellman
uin	2407
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>Public Health England has published guidance on homelessness for healthcare professionals and commissioners. This includes a link to the health audit toolkit developed by Homeless Link to help local authorities, charities and health services to gather information about the health needs of people experiencing homelessness in their area. Findings are available at:</p><p><a href="http://www.homeless.org.uk/facts/homelessness-in-numbers/health-needs-audit-explore-data" target="_blank">http://www.homeless.org.uk/facts/homelessness-in-numbers/health-needs-audit-explore-data</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 06/07/2017 09:52:05 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	484 label Biography information for Dame Louise Ellman